巨子生物(02367)发布公告，于2026年1月5日斥资1358.16万港元回购40万股。 ...

智通财经APP讯，巨子生物(02367)发布公告，于2026年1月5日斥资1358.16万港元回购40万股。 ...

格隆汇1月5日丨巨子生物(02367.HK)公告，1月5日耗资1358.2万港元回购40万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 巨子生物控股有限公司 呈交日期： 2026年1月5日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02367 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | | | | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股 ...

枭雄要成就霸业，需要的不只是一招鲜，而是长期源源不断的竞争力。 陕西女首富范代娣和前山东女首富赵燕，如果不做医美，不关注护肤成分，你可能对这两个名字并不熟 悉。但在如今的中国商业版图上，这两位女性，分别掌控着两家市值几百亿的上市公司——巨子生物和 华熙生物。 表面上看，她们一个在西安，一个在山东；一个做蛋白，一个做多糖；一个出身严谨的大学实验室，一 个来自野蛮生长的地产江湖。她们本该井水不犯河水。 但现实是，这两家公司正在进行一场旷日持久的、甚至可以说是「你死我活」的商战。 但命运和机遇有时候就是不讲道理。 这一年，在北大EMBA的课堂上，她结识了山东省生物药物研究院的副院长郭学平。他跟赵燕说了一句 至今被奉为行业金句的话：「一个玻尿酸分子，能锁住1000个水分子。」 故事的起点，要回到2000年。 这是一个神奇的年份，两人的命运在这一年同时被改写。 当时的赵燕，还是一个在海南淘金成功、在北京开发楼盘的地产大鳄。后来更是在北京开发了中环世贸 中心，承建了奥运会场馆五棵松体育馆，也就是现在的五棵松华熙Live。 按理来说，她的头衔，应该是地产女王，而不是现在的「玻尿酸女王」。 01 她没有亲自去搞研发，而是用资 ...

Core Viewpoint - The Chinese cosmetics industry is projected to reach a market size of 1.1 trillion yuan, with domestic brands surpassing international brands in market share and consumer preference [1][2]. Group 1: High-Quality Development and New Productive Forces - The domestic cosmetics market retail sales are expected to reach 470 billion yuan by 2025, indicating a significant growth trajectory for the industry [2]. - New productive forces are essential for the high-quality development of the cosmetics industry, transitioning from traditional manufacturing to intelligent and lean production [4]. - New productive forces enhance production efficiency and product consistency through automation and intelligent equipment, addressing quality control challenges [4]. Group 2: Intelligent Manufacturing Practices of Domestic Brands - The past decade has seen a shift in the cosmetics manufacturing industry from experience-driven to data-driven processes, evolving through three stages: semi-automated, automated, and now data-driven intelligent stages [6]. - Leading brands like Han Shu and Pechoin have made significant investments in intelligent manufacturing, achieving production capacity increases and improved quality control [8][10]. - Domestic brands have made historical advancements in intelligent manufacturing, with automation rates rising from approximately 40% to levels comparable to international brands [10]. Group 3: R&D Innovation and Cost Management - R&D expenditure rates vary across different categories, with skincare products averaging 1.5%-5% and medical beauty products at 2%-5%, reflecting a focus on compliance and clinical data [21][23]. - Domestic brands like Han Shu and Pechoin have R&D personnel ratios comparable to international leaders, indicating strong R&D capabilities [24]. - The production cost rates for various product categories range from 15% to 30%, with domestic brands leveraging self-researched technologies and integrated supply chains to maintain competitive pricing [27][28]. Group 4: International Competitiveness of Domestic Brands - Domestic brands have achieved significant breakthroughs in the cosmetics sector, enhancing core competitiveness through new productive forces [31]. - Intelligent manufacturing has enabled micro-level quality control, establishing trust in product quality [33]. - The integration of AI and 5G technologies in manufacturing processes positions domestic brands at the forefront of global standards, driving high-quality development in the industry [33].

Core Insights - Jiangsu Chuangjian Medical's "cross-linked recombinant collagen implant" has been approved by the National Medical Products Administration, marking a significant milestone in the domestic regenerative collagen market [1][12] - The medical aesthetics industry is shifting from simple volume filling to advanced needs for tissue regeneration, with regenerative materials like collagen gaining popularity due to their ability to stimulate the body's own collagen production [1][6] Market Overview - The Chinese medical aesthetics injection market is projected to grow from 21.2 billion RMB in 2023 to 65.3 billion RMB by 2028, with a compound annual growth rate (CAGR) of 25.3% [5] - The regenerative anti-aging injection segment is expected to increase its market share from 3% in 2019 to 31% by 2028, indicating it is the fastest-growing sub-market [5][6] Product Categories - Medical aesthetic injectables can be categorized into hyaluronic acid, botulinum toxin, and regenerative anti-aging materials, with the latter focusing on long-term tissue regeneration rather than just physical filling [3][4] - Regenerative anti-aging injectables are further divided into microsphere regeneration, collagen-based, PDRN, and other categories, emphasizing their role in improving skin quality and addressing aging [4][5] Competitive Landscape - The domestic market for regenerative anti-aging injectables is characterized by a mix of domestic and imported products, with companies like Jinjian Biological, Juzi Biological, and Chuangjian Medical forming a competitive triad [7][12] - As of 2025, there are 15 approved collagen implant products in China, with a notable presence of both animal-derived and recombinant collagen products [10][11] Innovation and Development - Companies are focusing on R&D and regulatory compliance to enhance product quality and market acceptance, with a trend towards stricter approval processes for medical devices [13][14] - Innovations in collagen types and structures are crucial for clinical applications, with companies like Chuangjian Medical achieving significant advancements in the stability and effectiveness of their products [17] Future Trends - The integration of recombinant collagen with microsphere components is expected to create new product forms and market opportunities, positioning domestic companies to play a more significant role in the global medical aesthetics market [19]

Group 1 - The top three companies with the highest short positions are Vanke Enterprises (02202), Dongfang Electric (01072), and COSCO Shipping Holdings (01919), with short ratios of 18.64%, 17.51%, and 16.68% respectively [1][2] - The company with the largest increase in short positions is Dongfang Electric (01072), which saw an increase of 2.20% from the previous short ratio [1][2] - The companies with the largest decrease in short positions include Sanhua Intelligent Control (02050), Tianqi Lithium (09696), and Yuejiang (02432), with decreases of -1.42%, -0.82%, and -0.71% respectively [1][3] Group 2 - The latest short position data shows that Vanke Enterprises has 411 million shares shorted, while Dongfang Electric has 71.45 million shares, and COSCO Shipping Holdings has 480 million shares shorted [2] - The companies with the largest increases in short positions also include JAKS Resources B (01167) and CSPC Pharmaceutical Group (01093), with increases of 0.77% and 0.56% respectively [2] - The companies with the largest decreases in short positions also include Ganfeng Lithium (01772) and Sunac China (01918), with decreases of -0.68% and -0.55% respectively [3][4]

Market Overview - The Hong Kong stock market opened slightly lower on December 31, with the Hang Seng Index down 0.21% at 25,801.49 points, the Hang Seng Tech Index down 0.22% at 5,566.24 points, and the National Enterprises Index down 0.23% at 8,970.49 points [1] - Major tech stocks mostly declined, with Alibaba down 0.55%, Tencent down 0.42%, and JD.com down 1.32%. Conversely, Xiaomi rose by 0.86% [1] Company News - Zijin Mining (02899.HK) expects to achieve a net profit of approximately RMB 51-52 billion for the fiscal year 2025, representing a year-on-year increase of about 59%-62% due to increased production and sales prices [2] - Starry Development (00640.HK) reported revenue of approximately HKD 835 million for the fiscal year ending September 30, 2025, a year-on-year increase of 13.4%, and a net profit of approximately HKD 122 million, up 21.7% [2] - Shanghai Electric (02727.HK) plans to sell a 47.4% stake in Electric Guoxuan and waive its preemptive rights to an additional 3.6% stake [3] - CNOOC Services (02883.HK) has recently purchased bank wealth management products totaling HKD 3 billion [4] Clinical Trials and Drug Approvals - Fosun Pharma (02196.HK) has initiated clinical trials for its integrated diagnosis and treatment nuclear medicine project SRT-007 within China [5] - Hutchison China MediTech (00013.HK) announced that its new drug application for Savolitinib, intended for treating gastric cancer patients with MET amplification, has been accepted and prioritized for review [5] Strategic Partnerships - Linkong Biotechnology Group (00690.HK) has established a strategic partnership with Wenzhou Medical University National Engineering Research Center and the Ouhai District People's Government [6] Financing Activities - Youlian International Education Leasing (01563.HK) has entered into a financing lease agreement for energy-saving equipment [7] Stock Buybacks - Tencent Holdings (00700.HK) repurchased 1.062 million shares for HKD 636 million at prices ranging from HKD 594.5 to HKD 600.5 [8] - COSCO Shipping Holdings (01919.HK) repurchased 4.3715 million shares for HKD 61.05 million at prices between HKD 13.86 and HKD 14.06 [9] - China Feihe (06186.HK) repurchased 8.837 million shares for HKD 36.34 million at prices between HKD 4.07 and HKD 4.12 [10] - Kuaishou-W (01024.HK) repurchased approximately 464,000 shares for HKD 29.88 million at prices between HKD 63.75 and HKD 64.75 [10] - Giant Bio (02367.HK) repurchased 400,000 shares for HKD 13.44 million at prices between HKD 33.48 and HKD 33.76 [11] Institutional Insights - Everbright Securities notes that the overall profitability of Hong Kong stocks remains strong, with relatively scarce assets in internet, new consumption, and innovative pharmaceuticals. Despite recent gains, valuations are still considered low, suggesting long-term investment potential [12] - Founder Securities highlights positive signals from government policies aimed at optimizing the "two new" policies, which may enhance the competitive environment in the automotive industry [12] - CITIC Securities anticipates a 7.9% increase in Hong Kong private residential transaction volumes in 2026, driven by a favorable interest rate environment and increased asset allocation demand [12]

证券时报·数据宝统计，巨子生物在港交所公告显示，12月30日以每股33.480港元至33.760港元的价格回 购40.00万股，回购金额达1344.08万港元。该股当日收盘价33.540港元，下跌2.95%，全天成交额3.85亿 港元。 | 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.12.30 | 40.00 | 33.760 | 33.480 | 1344.08 | | 2025.12.29 | 40.00 | 34.760 | 34.280 | 1381.44 | | 2025.12.23 | 40.00 | 36.480 | 35.740 | 1439.66 | | 2025.12.22 | 40.00 | 36.340 | 35.860 | 1442.97 | | 2025.12.19 | 40.00 | 35.520 | 34.540 | 1405.36 | | 2025.12.18 | 40.00 | 35.040 | 34.420 | 1388.30 | | ...